



VALUE OF PHARMACEUTICAL BENEFIT MANAGEMENT

High volume processing



Chronic medication registrations



Automated re-pricing



Office Line: +27 11 671 2000

E-mail: Partner@medscheme.co.za

Head office: 37 Conrad Road, Florida North, Roodepoort, 1709

Postal address: PO Box 1101, Florida Glen, 1708

Medscheme Holdings (Pty) Limited Reg No 1970 | 015014 | 07

www.medscheme.com




PHARMACEUTICAL BENEFIT MANAGEMENT

The cost, range and sophistication of medication is increasing rapidly

The introduction of expensive biological therapies and complexity of treatment plans have increased the financial burden on health-care funders. Innovative

strategies, technologies and expert clinical skills in the form of pharmaceutical benefit management programmes are needed to manage this increased financial burden.

Price growth of branded vs generic medication, Express Scripts 2012



KEY BENEFITS

- A long history of managing chronic, biological and oncology medication utilisation through technologies that enable instant electronic assessment, re-pricing, payment and tracking of these medications.
- Our large team of experienced pharmacists, physicians and consultants manage these programmes from delivering novel formularies through to managing large-scale pharmaceutical benefit programmes.
- Prescription medication pre-authorisation and claims management is continuously improved by a multi-disciplinary team from our Health Policy Unit who maintain a large database of health technology assessments.
- The programme is supported by price analysis, generic reference pricing initiatives, cost and prescription trend data analysis of our Health Intelligence Unit.



Our world-class pharmaceutical benefit management programme has helped get the right medication to patients in a fast and affordable way.



01 Formulary consulting

1.1 Formulary development

The design of an evidence-based formulary that is appropriate to the benefit structure. Our intelligent design process results in formularies that are customisable per client with a focus on access, cost-effectiveness and quality. This may include a list of medication that are automatically excluded for funding based on clinical and/or benefit-design grounds, e.g. herbal supplements.

1.2 Reference pricing

Medication in a specific drug class is reference priced to an appropriate generic or reference agent. This allows for variable co-payments and/or partial funding in cases where the price of the prescribed medicine is above that of the reference price.

1.3 Clinical coding

Our advanced pharmaceutical rules engine supports the creation of bespoke clinical and funding rules. This enables the automation of authorization in line with benefit design.

1.4 Health Policy Unit (HPU)

This unit is responsible for the continual review and updating of all relevant pharmaceutical protocols and Health Technology Assessments (HTA) in line with local and international best practice. Academic subject matter experts support them in these reviews.

1.5 Oncology programme design

Design of the appropriate oncology pharmaceutical programme is in line with the benefit design and underpinned by local and international oncology guidelines.

2.3 Pharmacist utilisation review

Scripts routed for intervention by the rules engine due to the requirement to obtain further information (e.g. the member's cholesterol level), member queries and specific clinical rules are reviewed by experienced pharmacists.

2.4 Medical advisor review

Experienced medical doctors in conjunction review complicated cases in conjunction with the patient's provider to expedite outcomes.

2.5 Expert committee

Pharmaceutical management can become highly technical or controversial, requiring the input of an experienced peer review committee. This committee meets weekly to review complex clinical cases and provide input on funding protocols.



03 Health-care technology platform

3.1 Pharmaceutical benefit management system

A custom built, scalable infrastructure for the transactional management of PBM programmes.

3.2 Data interchange

The system switches healthcare claims electronically and gives immediate responses directly from administrators in real time through state-of-the-art systems.

Flexible systems are able to handle the demands of multiple different third party administrators managing a variety of health insurers and medical schemes, each with vastly different demographics, health-care plan structures and multiple benefit options.



02 Administration and intervention

2.1 Prescription medicine registration

Chronic medication scripts are captured and coded on the appropriate pharmaceutical benefit management system, thus enabling electronic processing and validation.

2.2 Medicine Exclusion List (MEL) and reference pricing

Scripts are automatically validated and processed. Excluded medication is automatically rejected and the amount that will be funded calculated with co-payment if applicable.



04 Health intelligence reporting

4.1 Utilisation analysis and service level reporting

Reports on claims, medication bought and patterns in prescribing

4.2 Disease profiling

Profiling of patient group's risk adjusted in line with their disease coding and pharmaceutical prescribing patterns

4.3 Risk management

Pro-active reporting on new therapies, prescribing trends and future risks.

Sustainable health-care through cost risk management and outcomes improvement

